Targeted agents in second-line bladder cancer therapy

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1003-1015

  Gerullis, Holger ^a,b,c   Otto, Thomas ^a,b,c   Ecke, Thorsten H ^d  

^a Lukaskrankenhaus GmbH   (Germany)

^b Evaluation of Innovative Techniques in Medicine (DZITM)   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

bladder cancer; mammalian target of rapamycin inhibitor; second line; targeted therapy; transitional carcinoma; tyrosine kinase inhibitor

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOVITINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VANDETANIB; VINFLUNINE; VOLASERTIB;

ADD ON THERAPY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APPETITE DISORDER; ASTHENIA; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYSTECTOMY; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TARGETING; DRY SKIN; DYSPNEA; EDEMA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INSOMNIA; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEURALGIA; NEUTROPENIA; NONHUMAN; PALLIATIVE THERAPY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UROTHELIUM; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84867576120     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283582a33     Document Type: Review

References (117)

1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239-249.
2. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
3. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
4. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461.
5. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: Short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22:288-294.
6. Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638-2646.
7. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 2009; 30:2047-2052.
8. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, et al. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 2010; 31:1387-1391.
9. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW,Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23:675-680.
10. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004; 93:143-150.
11. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8:2339-2347.
12. Schedel F, Pries R, Thode B,Wollmann B,Wulff S, Jocham D, et al. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep 2011; 25:763-768.
13. Milowsky M. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011; 29 (Suppl):4606.
14. Seront E. A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy. J Clin Oncol 2010; 28 (Suppl):e15087.
15. Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 2012 [Epub ahead of print].
16. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008; 9:55-61.
17. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res 2006; 25:145-160.
18. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7:1957-1962.
19. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24:5552-5564.
20. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006; 175:1245-1252.
21. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6:4422-4431.
22. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: A trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4090-4095.
23. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28:1373-1379.
24. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115:2881-2890.
25. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010; 105:317-321.
26. Grivas P. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). San Francisco: ASCO-GU; 2012.
27. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, et al. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer [abstract]. J Clin Oncol 2011; 29 (Suppl 7):259.
28. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 2011; 78:233 e7-13.
29. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-619.
30. Sonpavde G, Jian W, Liu H,Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27:391-399.
31. Bellmunt J, Gonzalez-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011; 22:2646-2653.
32. Theodore C. Multicenter phase II study of sunitinib in patients with transitional cell carcinoma of the urothelium who failed or progressed after first line chemotherapy for locally advanced or metastatic disease. Preliminary results. [abstract]. Ann Oncol 2010; 21 (Suppl 8):900.
33. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4:677-685.
34. Wilhelm SM, Carter C, Tang L,Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
35. Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998; 76:189-193.
36. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003; 170:1987-1993.
37. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: A study of the PMH Phase II Consortium. Invest New Drugs 2011; 29:1045-1049.
38. Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V. Dasatinib: An antitumour agent via Src inhibition. Curr Drug Targets 2011; 12:563-578.
39. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-141.
40. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30:507-512.
41. Necchi A, Nadia Z, Mariani L, Nicolai N, Giannatempo P, Crippa F, et al. Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib in refractory urothelial cancer. Ann Oncol 2012; 23 (Suppl 1):i15-i25.
42. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
43. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36:127-137.
44. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55:510-513.
45. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166:1275-1279.
46. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004; 171 (Pt 1):570-574.
47. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003; 22:3361-3370.
48. Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005; 5:713-725.
49. Hoeben A, Landuyt B, Highley MS,Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56:549-580.
50. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
51. Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J, et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001; 51:1234-1240.
52. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11:861-870.
53. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28:207-214.
54. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010; 16:358-366.
55. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010; 76:923-926.
56. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 2001; 15:23-26.
57. Osai WE, Ng CS, Pagliaro LC. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 2008; 19:427-429.
58. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
59. J Clin Oncol 2011; 29:1525-1530.
60. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24:778-789.
61. Siefer-Radtke A. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. San Francisco: ASCO-GU; 2012.
62. McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology 2004; 63:619-624.
63. Jimenez RE, Hussain M, Bianco FJ Jr., Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7:2440-2447.
64. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65:1619-1625.
65. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69:1120-1125.
66. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155:321-326.
67. Wood DP Jr, Fair WR, Chaganti RS. Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J Urol 1992; 147:274-277.
68. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Molecular pathways in bladder cancer: Part 1. BJU Int 2005; 95:485-490.
69. Tsai YS, Tzai TS, Chow NH. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 2007; 79:210-216.
70. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003; 89: 1305-1309.
71. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 2002; 102:514-518.
72. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004; 90:1679-1685.
73. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007; 6:277-285.
74. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10:4874-4884.
75. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009; 20:1074-1079.
76. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102. BJU Int 2008; 101:20-25.
77. Ying H, Biroc SL, LiWW, Alicke B, Xuan JA, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5:2158-2164.
78. Yang JL, Qu XJ, Hayes VM, Brenner PC, Russell PJ, Goldstein D. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 2007; 99: 1539-1545.
79. Jacobs MA, Wotkowicz C, Baumgart ED, Neto BS, Rieger-Christ KM, Bernier T, et al. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007; 178 (Pt 1): 1510-1514.
80. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int 2010; 106:349-354.
81. Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep 2008; 10:10-17.
82. Dhillon S,Wagstaff AJ. Lapatinib. Drugs 2007; 67:2101-2108, discussion 9-10.
83. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007; 40:580-594.
84. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens - evidence of schedule-dependent synergy. Urology 2007; 69:390-394.
85. LoRusso PM, Jones SF, Koch KM, Arya N, Fleming RA, Loftiss J, et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008; 26:3051-3056.
86. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29:1050-1058.
87. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner- Wasik M, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29:2312-2318.
88. Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol 2010; 28:8-14.
89. Quesnelle KM, Grandis Jr. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935-5944.
90. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-265.
91. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
92. Bhuvaneswari R, Gan YY, Soo KC, Olivo M Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8:94.
93. Gandour-Edwards R, Lara PN Jr., Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 95: 1009-1015.
94. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2- overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895.
95. Peyromaure M, Scotte F, Amsellem-Ouazana D, Vieillefond A, Oudard S, Beuzeboc P. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: Report on six patients. Eur Urol 2005; 48:771-775, discussion 5-8.
96. Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, Rochlitz C. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: Report on 7 patients. Eur J Cancer 2006; 42:2660-2661.
97. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25:2218-2224.
98. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001; 28:613-619.
99. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
100. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-122.
101. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-1428.
102. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3:59-70.
103. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978; 62:1219-1222.
104. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264-2270.
105. Rangel C, Niell H, Miller A, Cox C. Taxol and taxotere in bladder cancer: In vitro activity and urine stability. Cancer Chemother Pharmacol 1994; 33:460-464.
106. Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60:759-766.
107. Sridhar S. A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. J Clin Oncol 2009; (Suppl e15058): [Epub ahead of print].
108. Sridhar S. Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC) [abstract]. J Clin Oncol 2011; 29:241.
109. Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48:179-186.
110. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443-3449.
111. Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res 2010; 184:33-44.
112. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28:409-428.
113. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 2011; 80:433-449.
114. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010; 105:748-767.
115. Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med 2012; 136:504-509.
116. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y,Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850-1855.
117. Dreicer R. Second-line chemotherapy for advanced urothelial cancer: Because we should or because we can? J Clin Oncol 2009; 27:4444-4445.